Therapeutic inhibition of TRF 1 impairs the growth of p53 ‐deficient K‐Ras G12V ‐ induced lung cancer by induction of telomeric DNA damage
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Telomeres are considered anti-cancer targets, as telomere maintenance above a minimum length is necessary for cancer growth. Telomerase abrogation in cancer-prone mouse models, however, only decreased tumor growth after several mouse generations when telomeres reach a critically short length, and this effect was lost upon p53 mutation. Here, we address whether induction of telomere uncapping by inhibition of the TRF1 shelterin protein can effectively block cancer growth independently of telomere length. We show that genetic Trf1 ablation impairs the growth of p53-null K-Ras(G12V)-induced lung carcinomas and increases mouse survival independently of telomere length. This is accompanied by induction of telomeric DNA damage, apoptosis, decreased proliferation, and G2 arrest. Long-term whole-body Trf1 deletion in adult mice did not impact on mouse survival and viability, although some mice showed a moderately decreased cellularity in bone marrow and blood. Importantly, inhibition of TRF1 binding to telomeres by small molecules blocks the growth of already established lung carcinomas without affecting mouse survival or tissue function. Thus, induction of acute telomere uncapping emerges as a potential new therapeutic target for lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“…of senescent cells compared to Trf1 + / + K-Ras + /G12V p53 (cid:1) / (cid:1) MEFs 7 days post-plating (Supplementary Fig S1B), most likely reflecting an additive effect of K-Ras oncogene-induced senescence and Trf1 deficiency-induced senescence (Serrano et al , 1997; Martinez et al , 2009).”
Shelterin: the protein complex that shapes and safeguards human telomeres
de Lange, T. (2005) · Genes & Development · doi:10.1101/gad.1346005 · Cited by 3,056 · cited 1×
“The shelterin complex is composed of six core proteins, including the telomeric repeat binding factor 1 or TRF1 (de Lange, 2005).”
A survey of telomerase activity in human cancer
Shay, J. W., & Bacchetti, S. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00062-2 · Cited by 2,794 · cited 2×
“To maintain a minimum functional telomere length, 80 – 90% of human tumors reactivate telomerase (Kim et al , 1994; Shay & Bacchetti, 1997; Joseph et al , 2010), and the remaining activate an alternative mechanism to maintain telomeres, known as ALT, based on recombination between telomeric…”
Olovnikov (1973) · doi:10.1016/0022-5193(73)90198-7 · Cited by 1,847
TERT Promoter Mutations in Familial and Sporadic Melanoma
Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., Kadel, S., Moll, I., Nagore, E., Hemminki, K., et al. (2013) · Science · doi:10.1126/science.1230062 · Cited by 1,799 · cited 2×
“…its regulatory regions have been found associated with many different types of cancer (McKay et al , 2008; Wang et al , 2008; Rafnar et al , 2009; Shete et al , 2009; Petersen et al , 2010; Melin et al , 2012; Bojesen et al , 2013; Garcia-Closas et al , 2013; Horn et al , 2013; Huang et al , 2013).”
WATSON, J. D. (1972) · Nature New Biology · doi:10.1038/newbio239197a0 · Cited by 1,632
Bryan, T. M., Englezou, A., Dalla-Pozza, L., Dunham, M. A., & Reddel, R. R. (1997) · Nature Medicine · doi:10.1038/nm1197-1271 · Cited by 1,292 · cited 1×
“…telomere length, 80 – 90% of human tumors reactivate telomerase (Kim et al , 1994; Shay & Bacchetti, 1997; Joseph et al , 2010), and the remaining activate an alternative mechanism to maintain telomeres, known as ALT, based on recombination between telomeric sequences (Bryan et al , 1997).”
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179
Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts
Parrinello, S., Samper, E., Krtolica, A., Goldstein, J., Melov, S., & Campisi, J. (2003) · Nature Cell Biology · doi:10.1038/ncb1024 · Cited by 1,116
p53- and ATM-Dependent Apoptosis Induced by Telomeres Lacking TRF2
Karlseder, J., Broccoli, D., Dai, Y., Hardy, S., & de Lange, T. (1999) · Science · doi:10.1126/science.283.5406.1321 · Cited by 1,086
Cited by
Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies
Jafri, M. A., Ansari, S. A., Alqahtani, M. H., & Shay, J. W. (2016) · Genome Medicine · doi:10.1186/s13073-016-0324-x · Cited by 716
Dewson, G., Eichhorn, P. J. A., & Komander, D. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00633-y · Cited by 326
Telomeres and Telomere Length: A General Overview
Srinivas, N., Rachakonda, S., & Kumar, R. (2020) · Cancers · doi:10.3390/cancers12030558 · Cited by 304
Telomere-driven diseases and telomere-targeting therapies
Martínez, P., & Blasco, M. A. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201610111 · Cited by 257
Self-citationTargeting telomerase for cancer therapy
Guterres, A. N., & Villanueva, J. (2020) · Oncogene · doi:10.1038/s41388-020-01405-w · Cited by 256
Metadata
- Authors
- García‐Beccaria, M., Martínez, P., Méndez‐Pertuz, M., Martínez, S., Blanco‐Aparicio, C., Cañamero, M., Mulero, F., Ambrogio, C., Flores, J. M., Megias, D., Barbacid, M., Pastor, J., & Blasco, M. A.
- Venue
- EMBO Molecular Medicine
- Published
- 2015-05-13
- Volume
- 7
- Issue
- 7
- Pages
- 930-949
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W1905626781
- Cited by
- 55
- References
- 28
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic inhibition of TRF 1 impairs the growth of p53 ‐deficient K‐Ras G12V ‐ induced lung cancer by induction of telomeric DNA damage. https://app.cochat.ai/papers/10.15252/emmm.201404497
- The paper
- García‐Beccaria, M., Martínez, P., Méndez‐Pertuz, M., Martínez, S., Blanco‐Aparicio, C., Cañamero, M., Mulero, F., Ambrogio, C., Flores, J. M., Megias, D., Barbacid, M., Pastor, J., & Blasco, M. A. (2015). Therapeutic inhibition of TRF 1 impairs the growth of p53 ‐deficient K‐Ras G12V ‐ induced lung cancer by induction of telomeric DNA damage. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201404497
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.